STUDI PENGGUNAAN ERITROPOIETIN PADA PASIEN CHRONIC KIDNEY DISEASE DENGAN ANEMIA (Penelitian dilakukan di Instalasi Rawat Jalan RSUD KANJURUHAN Kabupaten Malang)

Background: Chronic Kidney Disease (CKD) is a condition characterized by
abnormalities in kidney structure or function lasting ≥3 months and has become a
global health problem with increasing incidence and mortality rates, including in
Indonesia. CKD is progressive and may lead to various complications, particularly
anemia due to decreased erythropoietin production, which is often exacerbated by
iron deficiency and chronic inflammation. Erythropoiesis-stimulating agents
(ESAs), such as erythropoietin, are used to increase hemoglobin levels and have
been proven effective in several studies. Therefore, this study aims to determine the
pattern of erythropoietin use in CKD patients with anemia.
Objective: To determine the pattern of erythropoietin use in patients with Chronic
Kidney Disease (CKD) and anemia, including type, dosage, route of administration,
frequency, and duration of therapy.
Methods: This study used a retrospective observational method with a quantitative
descriptive approach. Data were obtained from the medical records of Chronic
Kidney Disease patients undergoing outpatient care from January 2025 to January
2026. Data were analyzed using univariate analysis.
Results and Conclusion: A total of 60 Chronic Kidney Disease patients met the
inclusion criteria. The patterns of erythropoietin therapy included monotherapy (100%),
two-drug combination therapy (0), three-drug combination therapy (0), and switching
therapy (23%). Erythropoietin monotherapy with a dose of 1×3000 IU was the most
commonly used regimen, while two- and three-drug combinations were less
frequent. The switching pattern generally involved a transition from monotherapy
to a combination of erythropoietin with iron supplementation (ferrous fumarate)
and folic acid.